United Therapeutics Q2 2024 Earnings Report $363.65 +4.07 (+1.13%) (As of 05:45 PM ET) Earnings HistoryForecast United Therapeutics EPS ResultsActual EPS$5.85Consensus EPS $6.33Beat/MissMissed by -$0.48One Year Ago EPS$5.24United Therapeutics Revenue ResultsActual Revenue$714.90 millionExpected Revenue$691.87 millionBeat/MissBeat by +$23.03 millionYoY Revenue Growth+19.80%United Therapeutics Announcement DetailsQuarterQ2 2024Date7/31/2024TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptPress ReleaseSEC FilingUTHR Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by $2 Trillion Disappears Because of Fed's Secretive New Move (Ad)$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.Click here to see his new research now. United Therapeutics Earnings HeadlinesHere are Updates on United Therapeutics Corp. (UTHR)December 23 at 9:36 AM | insidermonkey.comLouis W. Sullivan Sells 26,209 Shares of United Therapeutics Co. (NASDAQ:UTHR) StockDecember 22 at 4:19 AM | americanbankingnews.com$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.December 23, 2024 | Stansberry Research (Ad)United Therapeutics (NASDAQ:UTHR) Downgraded to "Buy" Rating by StockNews.comDecember 21 at 3:17 AM | americanbankingnews.comInsider Sell: Louis Sullivan Sells 26,209 Shares of United Therapeutics CorpDecember 19, 2024 | gurufocus.comCautious Hold: United Therapeutics’ Promising UKidney Progress Amidst Regulatory HurdlesDecember 18, 2024 | markets.businessinsider.comSee More United Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like United Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on United Therapeutics and other key companies, straight to your email. Email Address About United TherapeuticsUnited Therapeutics (NASDAQ:UTHR), a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.View United Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
